Filing Details
Akebia Therapeutics, Inc. (NASDAQ:AKBA) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 05, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:AKBA
Akebia Therapeutics, Inc. (AKBA) Files Quarterly Report for Q0
Akebia Therapeutics, Inc. (NASDAQ:AKBA) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 05, 2026.
At publication ·
What changed
Akebia Therapeutics, Inc. (NASDAQ:AKBA) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Akebia Therapeutics filed its Q0 2026 quarterly report (Form 10-Q) with the SEC on November 5, 2026.
- The company's stock trades at $0.69 per share with a market capitalization of $347.6 million.
- The 10-Q filing contains unaudited financial statements and management commentary on business conditions and emerging risks.
Market Context
Akebia Therapeutics, Inc.'s stock currently trades at $0.69 with a market capitalization of $347.6M.
The 10-Q provides Akebia Therapeutics, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Akebia Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View AKBA Stock Page
Frequently Asked Questions
Where can I read AKBA's SEC filings?
Browse all filings on our AKBA SEC filings page.
What types of SEC filings does Akebia Therapeutics, Inc. file?
Public companies like Akebia Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.